Synthetic Peptide Analogues
PT-141
10mgC₅₀H₆₈N₁₄O₁₀
Key Research Findings
- Characterisation of the cyclic heptapeptide bearing a C-terminal carboxyl terminus.
- Published receptor-binding assay data at the MC3R and MC4R subtypes.
- In-vitro studies of central-nervous-system receptor distribution.
Overview
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin-receptor agonist carrying a free C-terminal carboxyl group. Supplied as a lyophilised powder for in-vitro research use only.
Mechanism of Action
Reported in published in-vitro studies as a melanocortin-receptor ligand with activity in MC3R and MC4R receptor-binding assays. Not intended for human or veterinary use.
Research Effects
MC3R / MC4R Receptor Binding
Extensive ResearchCharacterised in receptor-binding assays as a ligand of the MC3R and MC4R melanocortin-receptor subtypes.
Receptor-Distribution Studies
Moderate ResearchPublished in-vitro studies report receptor-distribution profiles across cell-line and tissue assays.
MC1R Cross-Reactivity
Moderate ResearchReceptor-selectivity studies report secondary MC1R binding under the assay conditions tested.
Laboratory Research Only — All information on this page is provided for scientific research purposes only. This is a certified reference material sample sold and distributed for laboratory research only.
Quick Facts
Research Status Key
